Global

AMR Has An Equity Problem

Novartis lowered Lp(a) but not cardiovascular risk. What went wrong?

Brain Tumour Surgery Is Getting Smaller. Access Cannot Stay Elite.

AstraZeneca’s Wainua lowered a disease-causing protein but did not reduce heart complications in a major trial

FDA Is Asking the Right AI Question: Who Watches the Model After Approval?

Parkinson’s Gets a Cleaner Dopamine Bet

Myasthenia Care Cannot Wait for Crisis

Bladder Cancer Is Moving Into the Immunotherapy Maintenance Era

Radiopharmaceuticals Just Got a Necessary No
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
